Navigation Links
Esperion Therapeutics Initiates Phase I Clinical Study for ETC-1002
Date:11/13/2009

PLYMOUTH, Mich., Nov. 13 /PRNewswire/ -- Esperion Therapeutics, a privately held biotechnology company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced that the company has initiated a Phase I clinical study for ETC-1002, the company's novel small molecule compound designed to beneficially regulate the levels of plasma lipids and lipoproteins. The single escalating dose study in healthy volunteers will be the first clinical study conducted by Esperion since the re-establishment of the company in May 2008.

ETC-1002 is being developed to treat dyslipidemia, an early-stage risk factor of coronary artery disease and associated metabolic syndromes. The compound targets lipid metabolism in two ways: first, by inhibiting fatty acid and cholesterol synthesis; and second, by enhancing oxidation of fatty acids. ETC-1002 therefore has the potential to lower LDL-C and triglycerides and also to increase HDL-C.

"Our pre-clinical research related to ETC-1002 has been very promising, and we are pleased to advance this new product candidate to clinical development. ETC-1002 is the flagship product of our dyslipidemia program, and it will also be the first product in our pipeline to reach clinical-stage development," said Roger Newton, PhD, FAHA, president and CEO of Esperion Therapeutics. "Just over a year and a half following the re-establishment of Esperion, we continue to progress toward our goal of bringing breakthrough cardiovascular and metabolic disease therapies to market."

Cardio-metabolic diseases are the leading cause of morbidity and mortality among men and women in industrialized countries around the world.

"We are very well positioned to move ahead with the development effort for ETC-1002 as we also advance our other promising pre-clinical research programs in both acute and chronic therapies to treat cardiovascular and metabolic disorders," Mr.
'/>"/>

SOURCE Esperion Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Axelar AB Presents the New Anticancer Agent AXL1717 at The AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, Massachusetts, USA
2. Hollis-Eden to Present Interim Data From Its Phase I/II Clinical Studies of Apoptone(R) (HE3235) at Molecular Targets and Cancer Therapeutics Conference
3. Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting
4. Nektar Therapeutics Reports Third Quarter 2009 Financial Results
5. Tolera Therapeutics Files IND Application for TOL101, Appoints OToole to Lead Clinical Operations
6. Amicus Therapeutics Announces Third Quarter 2009 Financial Results and Strategic Business Updates
7. Cell Therapeutics, Inc.s (CTI) Presentation at BIO Investor Forum to be Webcast
8. Oxygen Biotherapeutics, Inc. Expands Board of Directors
9. Cornerstone Therapeutics to Host Third Quarter 2009 Conference Call
10. Fate Therapeutics Announces Creation of Small Molecule Platform for Commercial Scale Reprogramming
11. Frost & Sullivan Recognizes Agile Therapeutics for Its Innovative Weekly Low-Dose Contraceptive Patch
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... Rhythm announced today the results of a ... novel ghrelin agonist for the treatment of diabetic gastroparesis ... RM-131 significantly accelerates early gastric emptying and reduces upper ... diabetic gastroparesis. The findings were presented at the Digestive ... and recently published in Clinical Gastroenterology and ...
(Date:5/20/2013)... Researchers from the Southern University of Denmark have ... the acne causing P.acnes bacteria. Researchers believe found that when ... oxygen deprived location to seek shelter and grow. When an ... ability to live in the open joint areas, causing inflammation ... The best acne treatment ” explains why starting a normal ...
(Date:5/20/2013)... 2013 On 25-28 July, 2013, UPCP ... Paris - the beautiful city of lights. , According ... is revolutionizing the medical world. Understanding and integrating genetic ... hallmark of this transformation. Much of the present medical ... epidemiologic studies of large cohorts that do not take ...
(Date:5/20/2013)... 20, 2013 In Early 2013, ... of biotoxin related illnesses , announced his vision for ... to advance his protocol for treating Chronic Inflammatory Response ... third physician to achieve certification in the Shoemaker Protocol. ... to practice the Shoemaker Protocol in other parts of ...
Breaking Biology Technology:Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Gastroparesis in Patients with Type 1 Diabetes 2Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Gastroparesis in Patients with Type 1 Diabetes 3Adult Acne Treatment, Probiotic Action Shares New Insight How Treating Acne May Help Reduce Body Pain 2The International Congress on Personalized Medicine - Up Close and Personalized 2013 in Paris 2Dr. Ritchie Shoemaker Certifies Third Physician in His Treatment Protocol for Chronic Inflammatory Response Syndrome (CIRS) 2
... EAST NORRITON, Pa., Sept. 14, 2011 Tengion, Inc. (NASDAQ: ... announced that Brian Davis, Vice President Finance and Chief Financial ... Life Sciences Conference on Monday, September 19, 2011, at 1:30 ... presentation can be accessed under "Calendar of Events" in the ...
... a new technique that uses a single UV laser pulse ... method that could help scientists study the mechanical forces at ... lasers are a commonly-used tool for cutting into tissue, but ... a time in a series of steps. If the initial ...
... N.C., Sept. 13, 2011 Microban recently conducted ... planktonic and biofilm growth on High Consistency Rubber ... manufacture of urinary catheters.  Urinary infections are a ... current technologies have had limited success in reducing ...
Cached Biology Technology:Tengion to Present at UBS Global Life Sciences Conference 2Microban Medical Silver Antimicrobial Technologies for HCR Silicone Achieve 5 Log Reductions in Bacteria Growth and Prevent Biofilm Formation 2
(Date:5/18/2013)... MD (May 19, 2013) The AGA Research Foundation ... and Damian Augustyn Award in Digestive Cancer, which will ... of Medicine at the University of Pennsylvania, Philadelphia, as ... in pancreas development, regeneration and cancer progression. , "The ... in honor of two distinguished clinicians and AGA Legacy ...
(Date:5/17/2013)... day, insects provide the white noise of the South, but ... year, the Southern air hangs heavy from the humidity and ... more than 140 species of frogs, toads and salamanders, is ... the ponds and swamps are the auditorium for their symphonic ... and Monitoring Initiative, or ARMI, have front-row seats. ...
(Date:5/17/2013)... iCargo project (Intelligent Cargo in Efficient and Sustainable Global ... to an improvement in the efficiency of intermodal loading ... decision making. It comprises 29 European organisations with experience ... It has a budget totalling 17,000,000 and a duration ... working to specify and develop the semantic components and ...
Breaking Biology News(10 mins):AGA Research Foundation grant furthers digestive cancer research 2Front-row seats to climate change 2Front-row seats to climate change 3Front-row seats to climate change 4New logistics services that will cut energy consumption and CO2 emissions 2
... Babies conceived during a period of famine are at ... new research published in the international journal Addiction. ... GGZ, and Erasmus University Rotterdam studied men and women ... of the Dutch hunger winter. Those whose mothers ...
... is available in German . , A ... researchers of the Robert Koch Institute (Berlin), the Max ... Suisse des Recherches Scientifiques (Ivory Coast) confirms the disease ... from humans to wild apes. The study also showed ...
... Learning and Memory at MIT report in the Jan. 24 ... to see, for the first time, the effect of blocking ... This revolutionary method allowed Susumu Tonegawa, Picower Professor of ... major memory-forming circuit in the brain affected learning and memory ...
Cached Biology News:Hungry mothers risk addiction in their adult children 2Great apes endangered by human viruses 2New MIT tool probes brain circuits 2
Printer paper for Model 680 series readers is used with the thermal printers of the Model 680 and Model 680 XR microplate readers. Supplied as 2 rolls....
... developed with the drug discovery process in ... and performance, Safire is the ideal instrument ... and high throughput screening. Safire is a ... offers a range of high speed detection ...
... This depletion cocktail is tailored ... cells from suspensions of non-human ... are separated using the StemSep ... negative selection system, achieving a ...
...
Biology Products: